Not sure why but since our chardonnay guzzling friends are still technically in the diabetes business, we should cover their earnings which were announced this morning and which for diabetes flat out sucked. Here are the highlights (well actually the lowlights is more appropriate) from the press release;
“In the second quarter, Lantus® sales were €758 million, down 16.2%. In the U.S., Lantus® sales decreased 33.7% to €284 million, mainly reflecting lower average net price and the increased contribution to the coverage gap related to Medicare Part D. In Europe, second-quarter Lantus® sales were €146 million . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.